Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04875975 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04875975 is a Phase 2 study that was terminated before completion, run by UCB Biopharma SRL. The registered enrollment target is 12 participants.
The verdict
NCT04875975, a Phase 2 study, was terminated before completion, sponsored by UCB Biopharma SRL.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, change in cognitive function, use of rescue medication, onset of seizure freedom and to assess safety and tolerability.
Interventions
- DRUG Placebo
- DRUG Rozanolixizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-09-27 |
| Est. Completion | 2024-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04875975
The ClinicalTrials.gov registry entry for NCT04875975 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04875975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04875975 about?
NCT04875975 is a clinical study titled "A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis". The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, change in cognitive function, use of rescue medication, onset of seizure freedom and to assess safety and tolerability.
What is the current status of trial NCT04875975?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-09-27. Estimated completion is 2024-04-26.
What interventions are being tested in trial NCT04875975?
The interventions under investigation include: Placebo (DRUG), Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT04875975?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.